These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11155746)

  • 21. Transurethral alprostadil for the treatment of erectile dysfunction: results of a multicentre trial.
    Li MK; Lim PH; Wong MY; Fok A; Chia SJ; Consigliere D; Adaikan PG; Moorthy P
    Ann Acad Med Singap; 2000 Nov; 29(6):727-31. PubMed ID: 11269978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis.
    Benevides MD; Carson CC
    J Urol; 2000 Mar; 163(3):785-7. PubMed ID: 10687977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of transurethral alprostadil (MUSE) (prostaglandin E1) for glans tumescence in a patient with penile prosthesis.
    Chew KK; Stuckey BG
    Int J Impot Res; 2000 Jun; 12(3):195-6. PubMed ID: 11045915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use.
    Mulhall JP; Jahoda AE; Ahmed A; Parker M
    Urology; 2001 Aug; 58(2):262-6. PubMed ID: 11489714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
    Shabsigh R; Padma-Nathan H; Gittleman M; McMurray J; Kaufman J; Goldstein I
    Urology; 2000 Jan; 55(1):109-13. PubMed ID: 10654905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.
    Williams G; Abbou CC; Amar ET; Desvaux P; Flam TA; Lycklama à Nijeholt GA; Lynch SF; Morgan RJ; Müller SC; Porst H; Pryor JP; Ryan P; Witzsch UK; Hall MM; Place VA; Spivack AP; Gesundheit N
    Br J Urol; 1998 Jun; 81(6):889-94. PubMed ID: 9666777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cavernous auto-injection therapy with prostaglandin E1.
    Nisén H
    Ann Chir Gynaecol Suppl; 1993; 206():69-73. PubMed ID: 8291874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Place of intra-urethral prostaglandin E1 for the treatment of erectile dysfunction].
    Amar E
    Contracept Fertil Sex; 1999; 27(7-8):548-52. PubMed ID: 10495573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The therapeutic and diagnostic potentials of the intra-corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction].
    Mzo EB; Dmitriev DG
    Ter Arkh; 1995; 67(10):45-8. PubMed ID: 8779105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracavernous prostaglandin E1 in erectile dysfunction.
    Linet OI; Neff LL
    Clin Investig; 1994 Jan; 72(2):139-49. PubMed ID: 8186662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dose-response study of alprostadil sterile powder (S.Po.) (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men.
    Choi HK; Adimoelja A; Kim SC; Soebadi DM; Seong DH; Garceau RJ
    Int J Impot Res; 1997 Mar; 9(1):47-51. PubMed ID: 9138059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Alprostadil Alfadex Study Group.
    Goldstein I; Auerbach S; Padma-Nathan H; Rajfer J; Fitch W; Schmitt L
    Int J Impot Res; 2000 Aug; 12(4):205-11. PubMed ID: 11079361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
    Polito M; d'Anzeo G; Conti A; Muzzonigro G
    BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment.
    Brock G; Tu LM; Linet OI
    Urology; 2001 Mar; 57(3):536-41. PubMed ID: 11248634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
    Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N
    J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraurethral prostaglandin improves quality of vacuum erection therapy.
    John H; Lehmann K; Hauri D
    Eur Urol; 1996; 29(2):224-6. PubMed ID: 8647152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
    Hirsch IH; Smith RL; Chancellor MB; Bagley DH; Carsello J; Staas WE
    Paraplegia; 1994 Oct; 32(10):661-4. PubMed ID: 7831071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostaglandin E1 in the long-term treatment of erectile dysfunction].
    Vrabec J
    Bratisl Lek Listy; 1992 Oct; 93(10):545-6. PubMed ID: 1288824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.